BioVie Clinical Data Reveals Bezisterim's Anti-Inflammatory Potential
Bezisterim shows promising homeostatic properties that are relevant to inflammation and age-related human disorders.
In clinical studies, patients treated with bezisterim experienced significant advantages in age deceleration compared to those on placebo, demonstrating compelling results.
This drug has been shown to modulate DNA methylation of proinflammatory genes and aid in the transition of M1 proinflammatory macrophages to M2 anti-inflammatory macrophages.
Additionally, bezisterim was linked to substantial gene regulation, yielding impressive results in pathways associated with neurodegenerative diseases and various biological processes.
Recently, BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, shared critical data during a presentation at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024).
Overview of the Presentation
The presentation titled “Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments” offered detailed clinical data that examined various analyses and measurements related to longevity and the management of inflammation.
Christopher L. Reading, BioVie’s Senior Vice President of the Alzheimer’s Disease Program, emphasized the importance of the findings. Cuong Do, BioVie’s President and CEO, noted that clinical data indicated patients treated with bezisterim experienced a two- to four-year advantage in age deceleration compared to those receiving placebo. This was assessed using various biological clocks, highlighting bezisterim's potential in addressing biological aging and chronic inflammation.
Insights into DNA Methylation
As people age, a natural process known as DNA methylation can influence gene expression. This process involves adding methyl groups to DNA, which can affect the function of various genes. The ARDD 2024 presentation underscored bezisterim’s capacity to modulate DNA methylation, showcasing its promising effects.
Clinical Trial Findings
The degree of DNA methylation can be monitored through biological clocks that assess an individual's biological age. Clinical trials demonstrated that bezisterim had a significant impact on age deceleration when compared to placebo. Specifically, metrics such as the SkinBlood Clock and Inflammation Age Clock revealed notable benefits for patients treated with bezisterim.
Moreover, DNA found in blood primarily comes from monocytes, lymphocytes, and granulocytes. The analyses from the clinical trial indicated that bezisterim might facilitate the transition of macrophages from an inflammatory state to a more anti-inflammatory one.
Bezisterim and Biological Pathways
Clinical observations shared at ARDD 2024 illustrated how bezisterim affects inflammatory pathways. It potentially modulates the methylation levels of genes responsible for producing inflammatory factors like TNF? and IL6. This suggests a therapeutic approach for managing chronic low-grade inflammation, which is thought to contribute to various diseases.
Furthermore, bezisterim exhibited a range of effects, including “fold enrichment” in pathways associated with diseases such as Alzheimer’s and Parkinson’s, along with influencing biological processes related to senescence and apoptosis.
Future Research Directions
Bezisterim (NE3107) represents a significant advancement as an oral, bioavailable, and BBB-permeable drug candidate. With potential applications for treating neurological disorders, including Alzheimer’s and Parkinson’s diseases, ongoing research and clinical trials are crucial for evaluating its efficacy and safety.
BioVie is also investigating bezisterim’s potential to address conditions related to long COVID, particularly focusing on alleviating symptoms such as cognitive dysfunction and fatigue.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is committed to advancing innovative therapies for critical health issues, particularly in the realm of neurological disorders and advanced liver diseases. Their drug candidate bezisterim specifically targets inflammatory activation pathways, demonstrating the potential to greatly enhance patients' quality of life.
The company is also leading a Phase 3 study for its Orphan drug candidate, BIV201, which aims to treat complications arising from chronic liver cirrhosis. BioVie is dedicated to meeting urgent health needs through cutting-edge research and clinical applications.
Frequently Asked Questions
What is bezisterim?
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable drug candidate currently being studied for its anti-inflammatory properties and potential to alleviate symptoms of neurological disorders.
How does bezisterim impact inflammation?
Clinical data indicates that bezisterim modulates DNA methylation of genes associated with inflammation, which may assist in transitioning macrophages from a pro-inflammatory to an anti-inflammatory state.
What were the key findings from the ARDD 2024 presentation?
The presentation emphasized bezisterim's capacity to provide significant age deceleration advantages in clinical trials and its effects on proinflammatory gene methylation.
Is BioVie involved in any other research?
Yes, BioVie is conducting clinical studies on bezisterim for neurological disorders and is also evaluating its Orphan drug candidate BIV201 for advanced liver disease.
How can I learn more about BioVie?
For more information, please visit BioVie's website or contact their investor relations for inquiries about their ongoing research and developments.
